Intraparenchymal delivery of GDNF towards a treatment for Parkinson’s disease

Abbreviations: 6-hydroxydopamine, (6-OHDA); adeno-associated virus, (AAV); Alzheimer’s disease, (AD); amyotrophic lateral sclerosis, (ALS); brain derived neurotrophic factor, (BDNF); Core Program for Intracerebral Transplantations, (CAPIT); central nervous system, (CNS); ciliary neurotrophic factor, (CNTF); cerebrospinal fluid, (CSF); dopamine, dopaminergic, (DA); deoxyribonucleic acid, (DNA); 3,4-dihydroxyphenylacetic acid, (DOPAC); Escherichia coli, (E coli); epidermal growth factor, (EGF); fibroblast growth factor, (FGF); À-amino butyric acid, (GABA); glial cell line-derived neurotrophic factor, (GDNF); GDNF family receptors-alpha 1 to 4, (GFRα1-4); homovanillic acid, (HVA); intracerebroventricular, (ICV); immunoglobulin (insulin-like) growth factor, (IGF); interleukin, (IL); 3,4-dihydroxyphenylalanine (levodopa), (L-dopa); 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine, (MPTP); magnetic resonance imaging, (MRI); nerve growth factor, (NGF); N-methyl-D-aspartate, (NMDA); neurotrophin, (NT); polymerase chain reaction, (PCR); PD, (PD); platelet-derived growth factor, (PDGF); positron – emission tomography, (PET); receptor tyrosine kinase, (Ret); recombinant-methionyl human GDNF, (r-metHuGDNF); substantia nigra pars compacta, (SNc); substantia nigra pars reticulata, (SNr); transforming growth factor, (TGF); tyrosine hydroxylase, (TH); tyrosine kinase, (Trk); Unified Parkinson’s Disease Rating Scale, (UPDRS)